An innovative clinical trial has emerged, focusing on the potential of gamified biofeedback in combination with play therapy to support children diagnosed with Autism Spectrum Disorder (ASD). This study, which has not yet begun recruiting participants, has been announced by Luiz Alexandre Viana Magno. Interested stakeholders may find this development particularly insightful for its exploration of behavioral interventions in a highly specialized domain. Researchers aim to assess the interplay between behavioral therapies and biofeedback technologies to develop more effective therapeutic tools for children with ASD.
What changed?
On January 10, 2026, a new clinical trial was formally disclosed on ClinicalTrials.gov. It focuses on the evaluation of gamified biofeedback, a novel behavioral intervention, alongside traditional play therapy for children diagnosed with Autism Spectrum Disorder (ASD). While the study is not yet open for recruitment, its announcement has generated considerable interest among clinical researchers, regulatory professionals, and industry stakeholders invested in the advancement of therapeutic technologies for ASD.
The novel aspect of this research is the integration of gamified biofeedback systems into therapy, which could potentially enhance engagement and therapeutic outcomes in children. Such approaches could pave the way for significant advancements in behavioral health technologies.
What are the key details of this clinical trial?
This clinical trial, sponsored by Luiz Alexandre Viana Magno, is designed to investigate three specific therapeutic interventions for children with ASD:
- Gamified Biofeedback: Behavioral technologies incorporating game-like elements combined with biofeedback monitoring.
- Play Therapy: Conventional play-based therapeutic methods used to encourage social and emotional development.
- Deactivated Biofeedback: A control approach for comparative analysis.
The trial will likely involve extensive outcome measures to evaluate the safety, efficacy, and usability of these interventions. Moreover, investigators hope to shed light on how gamified components might increase patient participation and improve therapeutic results.
The study’s intended purpose, performance characteristics, and safety parameters align with European MDR language, as it emphasizes evidence-based evaluation. However, the effectiveness and scalability of such technologies remain to be validated through robust investigations.
What are the potential clinical impacts?
The integration of gamified biofeedback into therapy could revolutionize pediatric behavioral interventions, making treatment more accessible and engaging for children with ASD. Current therapy models may encounter challenges such as low engagement or limited scalability. Gamified systems may address these concerns by leveraging real-time feedback and game mechanics to sustain attention and drive emotional progress in young patients.
If successful, this trial could provide valuable evidence supporting regulatory submissions, especially for medical devices aiming to integrate gamified behavioral monitoring systems. This also aligns with global trends pushing for more personalized, tech-enhanced interventions in mental health care.
Stakeholders, including regulatory teams, clinicians, and device developers, should closely monitor the trial outcomes for insights into potential application frameworks, market access opportunities, and associated compliance considerations.
Frequently Asked Questions
1. Who is conducting the study?
The study is sponsored by Luiz Alexandre Viana Magno.
2. What is the focus of the trial?
The trial will evaluate the use of gamified biofeedback, play therapy, and deactivated biofeedback as interventions for children with Autism Spectrum Disorder.
3. Is the trial currently recruiting?
No, the trial is not yet recruiting participants as of January 2026.
4. Where can I find more information?
Details are available on ClinicalTrials.gov via the provided link.
Conclusion
This clinical trial marks a significant step forward in exploring innovative approaches to ASD intervention. The inclusion of gamified biofeedback could demonstrate a tangible benefit compared to traditional therapies. This could open doors for similar therapeutic device developments in the future. Clinical, quality, and regulatory teams should evaluate the outcomes upon release to determine applicability to their respective operational goals.
Disclaimer
This article is intended for informational purposes only and does not constitute legal, financial, or clinical advice. Always consult a qualified professional for guidance tailored to your specific needs or circumstances.
Study Information Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07322640?term=medical+device